VyomeInc (@vyomeinc) 's Twitter Profile
VyomeInc

@vyomeinc

Innovation-driven healthcare platform leveraging the US-India special relationship - a $B dollar opportunity. To be Nasdaq: $HIND, taking over from $RSLS

ID: 1850970145646366720

calendar_today28-10-2024 18:37:42

15 Tweet

27 Followers

4 Following

Venkat Nelabhotla (@newvenkat) 's Twitter Profile Photo

Biotech is waking up. $XBI has held steady above $105 as investors eye Q4 catalysts β€” M&A momentum, pivotal trial readouts, and a friendlier rate backdrop. After years of consolidation, sentiment may finally be turning. #Biotech #XBI #LifeSciences #HealthcareInvesting #Biopharma

Venkat Nelabhotla (@newvenkat) 's Twitter Profile Photo

May this #Deepavali festival of lights remind us that sustained effort, clarity, and purpose ignite the brightest light. Health, wealth & conscious success flow when dedication crosses its threshold of brilliance. Wishing everyone light within and around. #HappyDeepavali

May this #Deepavali festival of lights remind us that sustained effort, clarity, and purpose ignite the brightest light. 

Health, wealth & conscious success flow when dedication crosses its threshold of brilliance.

Wishing everyone light within and around. 

#HappyDeepavali
Venkat Nelabhotla (@newvenkat) 's Twitter Profile Photo

No one should suffer in silence. πŸ’” Patients with advanced cancer often endure painful, malodorous wounds that affect not just health β€” but dignity and daily life. Vyome Holdings, Inc. $HIND our investigational program VT-1953 is focused on addressing this urgent unmet need without an FDA

No one should suffer in silence. πŸ’”
Patients with advanced cancer often endure painful, malodorous wounds that affect not just health β€” but dignity and daily life.

<a href="/VyomeInc/">Vyome Holdings, Inc.</a> $HIND our investigational program VT-1953 is focused on addressing this urgent unmet need without an FDA
Venkat Nelabhotla (@newvenkat) 's Twitter Profile Photo

Great analysis The Wall Street Journal. After years of silence, biotech is quietly rallying; and this time it feels real. Valuations are still reasonable; most stocks trade below 2021 peaks. Balance sheets stronger; leaner firms, longer cash runways. Big Pharma is buying again; M&A heating up as

Great analysis <a href="/WSJ/">The Wall Street Journal</a>. After years of silence, biotech is quietly rallying; and this time it feels real.

Valuations are still reasonable; most stocks trade below 2021 peaks.
Balance sheets stronger; leaner firms, longer cash runways.
Big Pharma is buying again; M&amp;A heating up as